Yeh, the real loss, aside from "change in fair value" calculations is about $1.3M, rather than $6.8m, making it closer to -.04+ for the quarter. And, for some accounting reasons the $187K in sales to Italian distributor couldn't be realized in the quarter, but will be reflected in next quarter. While we seem to have an update in sites where the trials will be held, no present enrollment numbers are offered--perhaps because no patients yet treated, etc. Company says its pressing its patent applications. We do know, of course, that it's possible for these themselves to have marketable value, even if the company never gets USA sales going (and FDA approval). Looks like cash burn was about 8-900K for the quarter.
real loss ? lol. the real loss is how much cash plc lost,they have $1.6 million left,perhaps enough to meet payroll and exspences 1 or two more qr.'s...................why in the world would plc give away 60 million shares for less than $7.5 million dollars when they say renal guard has a conservative estimate of $500 million dollar's ? would like to see the names behind the loaner who potentially could own above 60% of plc shares or steal plc in bankruptcy
Kit and console sales continue to dissappoint and show zero traction in available markets. The inability to book the revenue from the stocking order is odd and makes you wonder if an actual sale really took place. I wouldn't be surprised if they are deferring the purchase, based on the lack of interest. They better ramp up pretty quickly if they are going to make the 670K in revenue projected by Taglich.